EpimAb Biotherapeutics Inc.’s HKEX IPO Application Lapsed, Dual Antibody Pipeline Centered on EGFR/cMET
NewTimeSpace News: The Main Board listing application filed by EpimAb Biotherapeutics Inc. with the Stock Exchange of Hong Kong Limited on 18 December 2025 has lapsed after the six-month statutory validity period expired, with CITIC Securities and China Merchants Bank International acting as the original joint sponsors.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- ROKAE ROBOTICS (03752.HK): Plans A Share Listing on Shenzhen Exchange
- NEW HIGHER EDU (02001.HK): Sells Zhengzhou College for RMB 594 Million
- AKESO (09926.HK): Trustee Buys 150,000 Shares for HKD 8.5 Million
- GOLDSTONE CAP (01160.HK): Gives Up Review, Suspended from 23 Nov
- DOBOT (02432.HK): Trustee Buys 200,000 H Shares on Market